

I hereby certify that this correspondence (including materials identified herein as attached) is being deposited utilizing the "Express Mail Post Office to Addressee" service of the United States Postal Service under Mailing Label No. EV 323776572 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: June 3, 2003

Signature:


(Richard Zimmermann)

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
03 JUN 30 2003

03 JUN 30 AM 8:36

Docket No.: 27866/34810
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Gray, et al.

Application No.: 09/509165

Group Art Unit: 1648

Filed: June 12, 2000

Examiner: Li, Bao Q.

For: Macrophage Derived Chemokine (MDC),
MDC Analogs, MDC Inhibitor Substances, and
Uses Thereof

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The Applicant requests that the Patent and Trademark Office consider the references listed on the attached PTO/SB/08 during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. A copy of each reference on PTO/SB/08 is attached.

This Information Disclosure Statement is filed after the mailing date of a first Office Action on the merits, but before either a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise would close prosecution. Accordingly, the fee of \$180.00 set forth in § 1.17(p) is enclosed.

This Information Disclosure Statement is not intended to be an admission that any particular document is "material" pursuant to 37 CFR 1.56, or is "prior art" for this invention.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists.